Post by UNVEIL

625 followers

๐—จ๐—ก๐—ฉ๐—˜๐—œ๐—Ÿ ๐—ถ๐˜€ ๐—ฏ๐—ฎ๐—ฐ๐—ธ ๐—ฎ๐˜ ๐˜๐—ต๐—ฒ ๐—œ๐—–๐—š๐—ง ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ” (๐—ฆ๐—ฎ๐—ป๐—ผ๐—ณ๐—ถ ๐—–๐—ฎ๐—บ๐—ฝ๐˜‚๐˜€, ๐—š๐—ฒ๐—ป๐˜๐—ถ๐—น๐—น๐˜†, ๐— ๐—ฎ๐˜† ๐Ÿฎ๐Ÿณโ€“๐Ÿฎ๐Ÿด) Characterizing nanoparticles in the 20โ€“300 nm range โ€” AAVs, lentivirus, adenoviruses, retroviruses, LNPs, liposomes, EVs โ€” still takes too much sample, too much time, and too much specialized infrastructure for what most process and analytical teams actually need: a quantitative read on each individual particle, fast enough to inform the next decision. Our instrument measures, particle by particle: โ€ข Concentration โ€” absolute, in particles/mL โ€ข Mass โ€” which, combined with size, gives the empty / full ratio across viral vectors, phages, VLPs, and even LNPs โ€ข Size โ€” full distribution, not just an average From those primary measurements you directly get aggregation profiles, payload content, production yield, and batch-to-batch comparability โ€” on 10 ยตL of unlabelled sample, in about 10 minutes, on a platform designed to be GMP-compliance ready. We will be at our booth (nยฐ9) with the instrument running live. If you are developing viral vectors, LNPs, VLPs, phages, or EVs โ€” whether in early R&D, process development, or analytical QC โ€” come and see it characterize your particles in front of you. We are happy to discuss what it would change in your workflow, and equally happy to discuss what it would not. And if you are not attending ICGT, we would still be glad to talk โ€” feel free to reach out directly through our website. #ICGT2026 #AAV #LV #LNP #CMC MabDesign Network MabDesign Sanofi Laure Delhon